Novartis (NVS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $294.63B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | CH | CEO | Vas Narasimhan |
| IPO Date | 1996-11-07 | CAGR | 3.26% |
| Employees | 75,267 | Website | www.novartis.com |
| Div. Yield | 2.94% | Payout Ratio | 68% |
| Buy Back Yield | 2.33% | Total Yield | 5.27% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| Enterprise Value | $337.82B | P/E Ratio | 17.84 |
| Forward P/E | 15.95 | PEG Ratio | -1.39 |
| P/S Ratio | 5.35 | P/B Ratio | 7.06 |
| P/CF Ratio | 16.25 | P/FCF Ratio | 18.36 |
| EPS | $8.69 | EPS Growth 1Y | -3.35% |
| EPS Growth 3Y | 84.68% | EPS Growth 5Y | 67.85% |
| Revenue Growth 1Y | 0.81% | Gross Margin | 0.74% |
| Operating Margin | 0.3% | Profit Margin | 0.23% |
| ROE | 0.3% | ROA | 0.1% |
| ROCE | 0.18% | Current Ratio | 0.86 |
| Quick Ratio | 0.67 | Cash Ratio | 0.24 |
| Debt/Equity | 1.18 | Interest Coverage | 11.88 |
| Altman Z Score | 3.49 | Piotroski Score | 6 |
Novartis (NVS) valuation & financials
Novartis (NVS) has a market capitalization of $294.63B and trades at a price-to-earnings ratio of 17.8. It operates in the Healthcare sector (Drug Manufacturers - General).
Novartis's revenue grew +0.8% over the last year.
Novartis's next earnings report is scheduled for October 27, 2026 before market open; analysts estimate EPS of $2.26.
Novartis (NVS) — frequently asked questions
When does Novartis (NVS) report earnings next?
Novartis is expected to report earnings on October 27, 2026 before market open. Analysts estimate EPS of $2.26.
What is Novartis's market cap?
Novartis (NVS) has a market capitalization of $294.63B.
What is NVS's P/E ratio?
Novartis trades at a price-to-earnings ratio of 17.8, with trailing twelve-month EPS of $8.69.
How fast is Novartis growing?
Novartis's revenue grew +0.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)